- Home
- VYGR vs TLSI Comparison
VYGR vs TLSI Comparison
Compare VYGR & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYGR
- TLSI
- Stock Information
- Founded
- VYGR 2013
- TLSI 2010
- Country
- VYGR United States
- TLSI United States
- Employees
- VYGR N/A
- TLSI N/A
- Industry
- VYGR Biotechnology: Pharmaceutical Preparations
- TLSI Medical Specialities
- Sector
- VYGR Health Care
- TLSI Health Care
- Exchange
- VYGR Nasdaq
- TLSI Nasdaq
- Market Cap
- VYGR 231.9M
- TLSI 244.3M
- IPO Year
- VYGR 2015
- TLSI N/A
- Fundamental
- Price
- VYGR $4.69
- TLSI $4.73
- Analyst Decision
- VYGR Strong Buy
- TLSI Strong Buy
- Analyst Count
- VYGR 8
- TLSI 4
- Target Price
- VYGR $16.71
- TLSI $11.13
- AVG Volume (30 Days)
- VYGR 789.3K
- TLSI 118.6K
- Earning Date
- VYGR 11-11-2025
- TLSI 11-13-2025
- Dividend Yield
- VYGR N/A
- TLSI N/A
- EPS Growth
- VYGR N/A
- TLSI N/A
- EPS
- VYGR N/A
- TLSI N/A
- Revenue
- VYGR $42,580,000.00
- TLSI $35,990,000.00
- Revenue This Year
- VYGR N/A
- TLSI $56.79
- Revenue Next Year
- VYGR $107.10
- TLSI $54.15
- P/E Ratio
- VYGR N/A
- TLSI N/A
- Revenue Growth
- VYGR N/A
- TLSI 45.50
- 52 Week Low
- VYGR $2.65
- TLSI $3.42
- 52 Week High
- VYGR $8.28
- TLSI $5.88
- Technical
- Relative Strength Index (RSI)
- VYGR 62.56
- TLSI 48.36
- Support Level
- VYGR $4.32
- TLSI $4.42
- Resistance Level
- VYGR $5.06
- TLSI $4.67
- Average True Range (ATR)
- VYGR 0.29
- TLSI 0.23
- MACD
- VYGR 0.02
- TLSI -0.03
- Stochastic Oscillator
- VYGR 64.59
- TLSI 61.87
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.